GlassScriptPhysician profile
Abdul M Haseeb
NPI 1407897093
$156,758.22
in general payments reported to CMS, 2019-2025
45 companies · $20K in 2025
The $20K reported for 2025 was more than what 93% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10K · 2020: $10K · 2021: $24K · 2022: $23K · 2023: $45K · 2024: $25K · 2025: $20K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $61K · Consulting Fee: $17K · Travel and Lodging: $7,762 · Food and Beverage: $4,372 · Education: $104.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $61,358.25 |
| Consulting Fee | $16,508.50 |
| Travel and Lodging | $7,762.40 |
| Food and Beverage | $4,372.27 |
| Education | $103.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $91,807.80 | 2019-2025 | Opdivo, Opdualag |
| Exelixis INC. | $33,475.83 | 2019-2025 | Cabometyx |
| Sobi, INC | $21,871.10 | 2022-2024 | |
| Celgene Corporation | $2,597.42 | 2020-2025 | Opdualag, Pomalyst, Reblozyl |
| Astrazeneca Pharmaceuticals LP | $1,696.81 | 2020-2025 | Imfinzi, Farxiga, Enhertu |
| Rigel Pharmaceuticals, INC. | $1,170.00 | 2022 | |
| Glaxosmithkline, LLC. | $483.36 | 2020-2025 | Zejula, Jemperli, Ojjaara |
| Novartis Pharmaceuticals Corporation | $450.95 | 2019-2025 | |
| Amgen INC. | $409.77 | 2019-2022 | |
| Athenex Pharmaceutical Division, LLC | $350.00 | 2020 | |
| Daiichi Sankyo INC. | $246.88 | 2021-2025 | Enhertu, Injectafer, Datroway |
| Pharmacyclics LLC, An Abbvie Company | $218.89 | 2021-2023 | Epkinly, Imbruvica |
| Kite Pharma, INC. | $203.78 | 2019-2024 | Yescarta |
| Abbvie INC. | $200.79 | 2023-2025 | |
| Genentech USA, INC. | $141.37 | 2019-2021 |
Show all 44 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abdul Haseeb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.